Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class (i.v. Lipo and Glyco-peptides) in Patients With ABSSSI

Next Previous
Trial Profile

Retrospective Effectiveness Study of Dalbavancin and Other Standard of Care of the Same Class (i.v. Lipo and Glyco-peptides) in Patients With ABSSSI

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dalbavancin (Primary) ; Daptomycin; Teicoplanin; Vancomycin
  • Indications Bacterial infections; Cellulitis; Erysipelas; Skin infections; Soft tissue infections; Wound infections
  • Focus Therapeutic Use
  • Acronyms REDS

Most Recent Events

  • 12 May 2021 Status changed from recruiting to completed.
  • 31 Jul 2020 Status changed from not yet recruiting to recruiting.
  • 11 Mar 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top